GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Debt-to-EBITDA

Lobe Sciences (XCNQ:LOBE) Debt-to-EBITDA : -0.17 (As of Feb. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lobe Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.37 Mil. Lobe Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. Lobe Sciences's annualized EBITDA for the quarter that ended in Feb. 2024 was C$-2.18 Mil. Lobe Sciences's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lobe Sciences's Debt-to-EBITDA or its related term are showing as below:

XCNQ:LOBE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.35   Med: -0.09   Max: -0.08
Current: -0.35

During the past 13 years, the highest Debt-to-EBITDA Ratio of Lobe Sciences was -0.08. The lowest was -0.35. And the median was -0.09.

XCNQ:LOBE's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs XCNQ:LOBE: -0.35

Lobe Sciences Debt-to-EBITDA Historical Data

The historical data trend for Lobe Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Debt-to-EBITDA Chart

Lobe Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.11 - - -0.08

Lobe Sciences Quarterly Data
Dec18 Mar19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Aug23 Nov23 Feb24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.05 N/A -0.17 -0.17

Competitive Comparison of Lobe Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Lobe Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lobe Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Debt-to-EBITDA falls into.



Lobe Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lobe Sciences's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.333 + 0) / -4.42
=-0.08

Lobe Sciences's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.368 + 0) / -2.18
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.


Lobe Sciences  (XCNQ:LOBE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lobe Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences (XCNQ:LOBE) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Lobe Sciences (XCNQ:LOBE) Headlines

No Headlines